Pharmaceutical company Corcept Therapeutics Inc. Friday said it has submitted a New Drug Application or NDA for the use of Corlux in Cushing's Syndrome to the US Food and Drug Administration or FDA.
Corcept Therapeutics submits NDA for the use of Corlux in Cushing's Syndrome